• Cabozantinib is the first and only monotherapy to demonstrate superior clinical efficacy over sunitinib in treatment-naïve patients with intermediate- or poor-risk aRCC

• Independent Radiology Review Committee confirms primary endpoint analysis per investigator: cabozantinib provided statistically significant improvement of progression-free survival, with a 52 percent reduction in the rate of progression or death compared to sunitinib
• Ipsen and Exelixis will host an investor and media webcast from Madrid to discuss the data on Sunday, September 10 starting at 18h45 CEST

• Positive opinion based on the results of two randomized Phase 3 trials, TELESTAR and TELECAST

Half-year IPSEN liquidity contract statement entered into with NATIXIS

Saol sales team to promote Dysport^® for select approved therapeutic indications  in U.S. hospitals

IRC confirms cabozantinib significantly improved progression-free survival compared to sunitinib

E.U. regulatory submission remains on track for Q3 2017

Adoption of all resolutions submitted to the vote of Shareholders

2020 sales to exceed €2.5 billion
driven by Specialty Care sales growth above 14% per year¹ with a Group Core Operating Income margin greater than 30% of sales

“Primary Care” division to become “Consumer Healthcare”

Strong operating performance exceeds guidance with Group sales up 11.8% driven by Specialty Care and Core Operating Margin improvement despite Cabometyx launch investments

Acquisition of Onivyde and new Primary Care products expected to close during the first half of 2017

Transaction leverages Primary Care infrastructure and accelerates conversion to OTx business model.

Ipsen to pay €83 million cash upon closing for the products.

Ipsen today announced the appointment of Harout Semerjian as President, Head of Specialty Care International Region & Global Franchises, effective February 2, 2017. He will report to David Meek, CEO of Ipsen, and will be a member of the Executive Leadership Team.

Half-year IPSEN liquidity contract statement entered into with NATIXIS

Under the terms of the agreement, Ipsen will gain exclusive commercialization rights for the current and potential future ONIVYDE indications in the U.S., as well as the current licensing agreements with Shire for commercialization rights ex-U.S. and PharmaEngine for Taiwan. The transaction also includes Merrimack’s commercial and manufacturing infrastructure, and generic doxorubicin HCl liposome injection.

• Amendment enhances productive year with CABOMETYX^TM regulatory approvals and commercial launches in the United States and European Union
• Exelixis to receive $10 million upfront payment, with subsequent regulatory and commercial milestones

Ipsen (Euronext: IPN; ADR: IPSEY) announced today its corporate agenda* for 2017: 

Alexandre Lebeaut, MD will lead the R&D division in the interim.

• Acceleration of Group sales growth at 12.2%¹ in the third quarter resulting in 10.5%¹ sales growth for the first 9 months driven by Specialty Care
• Guidance 2016 raised